MGMT promoter methylation in plasma of glioma patients receiving temozolomide

Valentina Fiano, Morena Trevisan, Elisa Trevisan, Rebecca Senetta, Anna Castiglione, Carlotta Sacerdote, Anna Gillio-Tos, Laura De Marco, Chiara Grasso, Michela Magistrello, Fabrizio Tondat, Roberta Rudà, Paola Cassoni, Riccardo Soffietti, Franco Merletti

Research output: Contribution to journalArticlepeer-review

Abstract

Promoter methylation of the O6-methylguanine-DNA methyltransferase (MGMT) gene plays a role in cellular response to alkylating agents. In the present study aimed to: (i) evaluate the concordance between MGMT promoter methylation status in tumor tissue and plasma; (ii) monitor MGMT promoter methylation status in plasma taken before and during temozolomide treatment; (iii) explore the value of MGMT promoter methylation status in plasma as a prognostic/predictive biomarker in glioma patients. We enrolled 58 patients with histologically confirmed glioma at different grades of malignancy. All patients underwent surgical resection and temozolomide treatment. Paraffin-embedded tumor tissue was available for 48 patients. Blood samples were collected from all patients before temozolomide treatment (baseline) and at each MRI examination for a 12-month period. MGMT promoter methylation status was assessed in both sample types by real time PCR with a specific probe. The frequency of MGMT promoter methylation was 60.4 % in tumor tissue and 41.38 % in plasma. MGMT promoter methylation status was concordant in the two sample types (Kappa = 0.75, 95 % confidence interval (CI) 0.57-0.93; p value

Original languageEnglish
Pages (from-to)347-357
Number of pages11
JournalJournal of Neuro-Oncology
Volume117
Issue number2
DOIs
Publication statusPublished - 2014

Keywords

  • Glioma
  • Methylation
  • MGMT
  • Plasma DNA
  • Temozolomide

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neurology
  • Medicine(all)

Fingerprint

Dive into the research topics of 'MGMT promoter methylation in plasma of glioma patients receiving temozolomide'. Together they form a unique fingerprint.

Cite this